What is the current revenue of the antimicrobial resistance surveillance market?

In 2027 the market for antimicrobial resistance surveillance is worth approximately USD 7.18 Billion.

What is the forecasted size of the antimicrobial resistance surveillance industry?

Antimicrobial Resistance Surveillance Market size stood at USD 6.82 Billion in 2026 and is predicted to grow at 6.15% CAGR from 2027 to 2036, reaching USD 12.39 Billion by 2036.

How is the growing burden of antimicrobial resistance influencing surveillance investments?

Rising antimicrobial resistance is driving expansion of surveillance systems that monitor resistance patterns, strengthen antimicrobial stewardship, improve infection control, and support timely clinical decision-making through continuous microbiological data analysis.

How are AI-enabled diagnostic platforms transforming antimicrobial resistance surveillance?

AI-powered diagnostic platforms accelerate analysis of microbiological data, identify resistance patterns more efficiently, and enable real-time reporting that improves surveillance responsiveness and supports faster clinical and public health interventions.

Why do diagnostic kits lead the antimicrobial resistance surveillance market?

Diagnostic kits accounted for 45.47% of the market in 2026 because they enable rapid identification of antimicrobial-resistant pathogens, improving treatment decisions, infection control, and surveillance across healthcare settings.

Why are hospitals the fastest-growing end-use segment in the antimicrobial resistance surveillance market?

Hospitals are the fastest-growing end-use segment, with a 48.44% market share in 2026, driven by increasing demand for resistance monitoring, infection prevention, antimicrobial stewardship, and management of healthcare-associated infections.

How does North America maintain its leading position in antimicrobial resistance surveillance?

North America accounted for 43.14% in 2026, supported by established healthcare systems, disease surveillance infrastructure, and strong investment in diagnostics and data management.

What is driving faster growth in Asia Pacific's antimicrobial resistance surveillance market?

Asia Pacific is growing fastest as infectious disease burdens, healthcare infrastructure, laboratory capabilities, and investment in antimicrobial stewardship and disease monitoring expand.

Which companies are driving growth in the antimicrobial resistance surveillance landscape?

Prominent companies in the antimicrobial resistance surveillance market include bioMérieux SA (France), Becton, Dickinson and Company (United States), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), Abbott Laboratories (United States), Bruker Corporation (United States), Qiagen N.V. (Germany), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche AG (Switzerland)